DFSV vs XBI
Dimensional US Small Cap Value ETF vs SPDR S&P Biotech ETF
- • DFSV has the lower expense ratio at 0.31% vs 0.35% for XBI.
Side-by-side metrics
| Metric | DFSV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.31% | 0.35% |
Dividend yield Trailing 12-month yield. | — | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $27.77B | $10.92B |
YTD return | 19.52% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.96 | 1.01 |
P/E ratio | 13.30 | — |
Last price | $39.35 | $156.41 |
Inception | — | — |
Issuer | Dimensional | State Street |
DFSV top holdings
| DINO | HF Sinclair Corp | 0.88% |
| ARW | Arrow Electronics Inc | 0.82% |
| BWA | BorgWarner Inc | 0.80% |
| AVT | Avnet Inc | 0.80% |
| ELAN | Elanco Animal Health Inc | 0.75% |
| IVZ | Invesco Ltd | 0.74% |
| KNX | Knight-Swift Transportation Holdings Inc Class A | 0.70% |
| OVV | Ovintiv Inc | 0.68% |
| JXN | Jackson Financial Inc | 0.65% |
| SWKS | Skyworks Solutions Inc | 0.65% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About DFSV
DFSV (Dimensional US Small Cap Value ETF) is Systematic small-cap value strategy from Dimensional. Managed by Dimensional, the fund carries $27.8B in assets under management, an expense ratio of 0.31%. Its largest holding is HF Sinclair Corp (DINO), which represents 0.9% of the portfolio. Real Estate is the fund's largest sector exposure at 0.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.